Penumbra’s Q1 Revenue Jumps 15.6% to $374.8 Million with $9.4M Acquisition Expense
Penumbra posted first-quarter revenue of $374.8 million, up 15.6% year-over-year, while logging $9.4 million in acquisition-related expenses tied to Boston Scientific’s pending takeover, eroding margins. The thrombectomy leader withheld full-year 2026 guidance due to the acquisition, signaling integration uncertainties that could affect Boston Scientific’s projected synergies and valuation.
1. Q1 Financial Performance
Penumbra generated $374.8 million in revenue for the quarter ended March 31, 2026, a 15.6% increase versus the prior year, driven by a 12.1% rise in global thrombectomy sales to $253.9 million and a 23.8% jump in embolization and access revenue to $120.8 million. Gross profit margin improved by 1.0 percentage point to 67.6%, while net income narrowed to $32.6 million from $39.2 million year-over-year.
2. Acquisition-Related Expenses and Guidance Suspension
SG&A expenses included $9.4 million of acquisition-related charges associated with Boston Scientific’s pending acquisition, contributing to total operating expenses of $215.2 million. Penumbra declined to provide full-year 2026 financial guidance or host a conference call, attributing the decision to uncertainty around the timing and completion of the acquisition.
3. Implications for Boston Scientific
The pending deal, if approved, would enhance Boston Scientific’s interventional neurology portfolio and broaden its thrombectomy offerings, but integration costs and regulatory timelines present potential risks. Observers will be watching for approval progress and cost synergies as key determinants of the acquisition’s impact on Boston Scientific’s valuation and earnings trajectory.